AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb IVRA with 0.1 mg of HIDA labelled with 100 muCi of 99mTc in 40 ml of saline; tourniquet inflated for 20 min.
Number of subjects: 10
Study 7547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb IVRA after tourniquet deflation; first 3 min post-deflation.
Number of subjects: 10
Study 7547041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb IVRA after tourniquet deflation; first 3 min post-deflation.
Number of subjects: 10
Study 1936585 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (2 micrograms.kg‐1.min‐1)
Number of subjects: 7
Study 1936585 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 6122738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 200mg twice daily for six weeks
Number of subjects: 48
Study 6122738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6122738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 100mg at night for one year as maintenance treatment
Number of subjects: 48
Study 30777772 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 147
Study 30777772 — intervention group
Group type: COMPARATOR
Intervention: Nondrinking control feedback
Number of subjects: 147
Study 28475678 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (20 g/day load×5 days followed by 2 g/day orally)
Number of subjects: 263
Study 28475678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to creatine)
Number of subjects: 263
Study 28475678 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 263
Study 28475678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 25524863 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum TENSIA in cheese (1×10^10 cfu)
Number of subjects: 0
Study 25524863 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum TENSIA in yoghurt (6×10^9 cfu)
Number of subjects: 0
Study 25524863 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 23404220 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier® EasyWarm® warming blanket
Number of subjects: 80
Study 23404220 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital duvet (control)
Number of subjects: 80
Study 22172255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus bifidus supplementation for 14 days after birth
Number of subjects: 50
Study 22172255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus bifidus supplementation
Number of subjects: 50
Study 22172255 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional management only)
Number of subjects: 50
Study 19586556 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 microg CIFN
Number of subjects: 144
Study 19586556 — intervention group
Group type: COMPARATOR
Intervention: 50 microg IFN-alpha1b
Number of subjects: 144
Study 18000538 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus azithromycin (1 g/day x 2 days)
Number of subjects: 141
Study 18000538 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus artesunate (200 mg/day x 3 days)
Number of subjects: 141
Study 18000538 — intervention group
Group type: COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP; 3 tablets, 500 mg sulfadoxine and 25 mg pyrimethamine per tablet)
Number of subjects: 141
Study 15207199 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention: mailing DI reports
Number of subjects: 0
Study 15207199 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic intervention: DI report delivered in collective session managed by a trained doctor
Number of subjects: 0
Study 15207199 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention: discussion peer-to-peer between FD and the trained doctor
Number of subjects: 0
Study 15207199 — intervention group
Group type: COMPARATOR
Intervention: Control group: no DI information received
Number of subjects: 0
Study 11448319 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I brachytherapy
Number of subjects: 1317
Study 11448319 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 1317
Study 9568678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with PSMA-derived peptides (PSM-P1 and PSM-P2)
Number of subjects: 0
Study 8043996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine 160 mg intravenously for 10 days
Number of subjects: 59
Study 8043996 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 59
Study 31898939 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus with standard-dose mycophenolate mofetil (MMF)
Number of subjects: 108
Study 31898939 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus with reduced-dose mycophenolate mofetil (MMF)
Number of subjects: 108
Study 30539929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity interprofessional simulation educational intervention
Number of subjects: 0
Study 30539929 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom lesson (Control Group)
Number of subjects: 0
Study 27151255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (up to 75 mg/day) for 7 or 13 weeks
Number of subjects: 0
Study 27151255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (up to 75 mg/day)
Number of subjects: 0
Study 27151255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (open-label treatment for ≥24 weeks)
Number of subjects: 0
Study 27151255 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 27151255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26700278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (12 weeks, 5 days/week, 60 min/day)
Number of subjects: 170
Study 26700278 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activities (control group)
Number of subjects: 170
Study 22960709 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - social stress induction through exclusion in a virtual ball game and negative feedback
Number of subjects: 76
Study 22960709 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - included in the game and received neutral feedback
Number of subjects: 76
Study 21079428 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 1670
Study 21079428 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) with HAART
Number of subjects: 1670
Study 18434189 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 47
Study 18434189 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day) + Naltrexone (50 mg/day)
Number of subjects: 47
Study 18434189 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day) + GHB (75 mg/kg)
Number of subjects: 47
Study 18434189 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day) + Naltrexone (50 mg/day) + GHB (75 mg/kg)
Number of subjects: 47
Study 16520204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 32
Study 16520204 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 32
Study 12660585 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% carteolol alginate once daily
Number of subjects: 151
Study 12660585 — intervention group
Group type: COMPARATOR
Intervention: 1% carteolol standard solution twice daily
Number of subjects: 151
Study 10942100 — intervention group
Group type: EXPERIMENTAL
Intervention: Better understanding of disease
Number of subjects: 214
Study 10942100 — intervention group
Group type: COMPARATOR
Intervention: Poor understanding of disease
Number of subjects: 214
Study 9098601 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer interpretation of ECG analysis
Number of subjects: 120
Study 9098601 — intervention group
Group type: COMPARATOR
Intervention: Visual interpretation of ECG analysis
Number of subjects: 120
Study 8097273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg oral dose, once a week)
Number of subjects: 84
Study 8097273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 3513516 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant and sustained-release verapamil
Number of subjects: 103
Study 3513516 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (control)
Number of subjects: 103
Study 3513516 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (all formulations)
Number of subjects: 103
Study 3513516 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 103
Study 29809024 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-family intervention
Number of subjects: 0
Study 29909024 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching training intervention
Number of subjects: 22
Study 29909024 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 22
Study 26919580 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐DWI with respiratory‐triggering (SMS‐RT)
Number of subjects: 22
Study 26919580 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐DWI with free breathing (SMS‐FB)
Number of subjects: 22
Study 26919580 — intervention group
Group type: COMPARATOR
Intervention: Standard DWI with respiratory‐triggering (STD‐RT)
Number of subjects: 22
Study 26919580 — intervention group
Group type: COMPARATOR
Intervention: Standard DWI with free breathing (STD‐FB)
Number of subjects: 22
Study 26919580 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐DWI (both breathing schemes)
Number of subjects: 22
Study 26919580 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS‐DWI
Number of subjects: 22
Study 24813776 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out vein graft as a cuff after direct suture (Group B)
Number of subjects: 10
Study 24813776 — intervention group
Group type: COMPARATOR
Intervention: Direct suture without vein graft (Group A)
Number of subjects: 10
Study 24813776 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out vein graft as a cuff (Group B)
Number of subjects: 10
Study 22142458 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml vodka (30 g alcohol) with 200 ml orange juice
Number of subjects: 24
Study 22142458 — intervention group
Group type: COMPARATOR
Intervention: Only orange juice
Number of subjects: 24
Study 20489017 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial genome sequencing
Number of subjects: 178
Study 18358083 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Number of subjects: 738
Study 18358083 — intervention group
Group type: COMPARATOR
Intervention: levofloxacin + ceftriaxone
Number of subjects: 738
Study 16103605 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrrh (Mirazid)
Number of subjects: 104
Study 16103605 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 104
Study 16103605 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (offered to individuals uncured after two myrrh treatments)
Number of subjects: 104
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment in women
Number of subjects: 959
Study 11941903 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment in men
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: One drug treatment
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination therapy
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Free combination therapy
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors/AT‐II antagonists
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 959
Study 11941903 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 959
Study 10024093 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch supplements
Number of subjects: 24
Study 10024093 — intervention group
Group type: COMPARATOR
Intervention: Conventional starches
Number of subjects: 24
Study 8636524 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of liquid 5% lidocaine
Number of subjects: 9
Study 8636524 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of 2% lidocaine paste
Number of subjects: 9
Study 2149050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (30 mg/kg/d)
Number of subjects: 151
Study 2149050 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 12 h on day 1, then daily)
Number of subjects: 151
Study 2149050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 151
Study 2149050 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 151
Study 2149050 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin and Teicoplanin
Number of subjects: 151
Study 398661 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg domperidone I.V.
Number of subjects: 47
Study 398661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg domperidone I.V.
Number of subjects: 47
Study 31923565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g kg‐1 Fishwort Powder (FWP)
Number of subjects: 320
Study 31923565 — intervention group
Group type: COMPARATOR
Intervention: Fishwort Powder (FWP)
Number of subjects: 320
Study 31094461 — intervention group
Group type: EXPERIMENTAL
Intervention: Umifenovir (Arbidol) 800 mg/day for 5 days (n=181)
Number of subjects: 359
Study 31094461 — intervention group
Group type: EXPERIMENTAL
Intervention: Umifenovir (Arbidol)
Number of subjects: 359
Study 31094461 — intervention group
Group type: COMPARATOR
Intervention: Placebo 4 times a day for 5 days (n=178)
Number of subjects: 359
Study 31094461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 29067426 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery (n=237)
Number of subjects: 471
Study 29067426 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (n=234)
Number of subjects: 471
Study 29067426 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery (n=235)
Number of subjects: 471
Study 29067426 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (n=224)
Number of subjects: 471
Study 29067426 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery
Number of subjects: 471
Study 29067426 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 471
Study 26757190 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (folic acid, vitamins B6 and B12)
Number of subjects: 266
Study 26757190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 26757190 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 266
Study 26118077 — intervention group
Group type: EXPERIMENTAL
Intervention: Homotoxicological medicines (Lymphomyosot, Galium‐Heel®, Traumeel S, Echinacea compositum S, Bronchalis‐Heel®, Mucosa compositum) in addition to standard anti‐inflammatory therapy
Number of subjects: 97
Study 26118077 — intervention group
Group type: COMPARATOR
Intervention: Standard anti‐inflammatory therapy
Number of subjects: 97
Study 21996132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 40 mg (n = 6)
Number of subjects: 13
Study 21996132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 60 mg (n = 7)
Number of subjects: 13
Study 21996132 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 13
Study 21996132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (both doses)
Number of subjects: 13
Study 19542895 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen for 15 min
Number of subjects: 30
Study 19542895 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 30
Study 19542895 — intervention group
Group type: COMPARATOR
Intervention: Baseline muscle sympathetic nerve activity
Number of subjects: 30
Study 17719273 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal in-hospital diuretic dose
Number of subjects: 395
Study 15808387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin starting dose of 2.5 mg bd
Number of subjects: 96
Study 15808387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin starting dose of 5 mg nocte
Number of subjects: 96
Study 15808387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 12150234 — intervention group
Group type: EXPERIMENTAL
Intervention: Studying names of 4 members of a hypothetical group
Number of subjects: 0
Study 9448164 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily, amoxicillin 500 mg t.i.d., metronidazole 500 mg t.i.d.
Number of subjects: 92
Study 9448164 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg t.i.d., metronidazole 500 mg t.i.d.
Number of subjects: 92
Study 9448164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-resistant H. pylori strains
Number of subjects: 92
Study 9448164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-sensitive H. pylori strains
Number of subjects: 92
Study 8554951 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms eformoterol
Number of subjects: 18
Study 8554951 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms eformoterol
Number of subjects: 18
Study 8554951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2121360 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg tablets once daily)
Number of subjects: 40
Study 2121360 — intervention group
Group type: COMPARATOR
Intervention: Phosphatidylserine (100 mg capsules twice daily)
Number of subjects: 40
Study 2121360 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 7381310 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer tutoring sessions with tutors who learned to correct and reinforce students in a nonhostile manner.
Number of subjects: 60
Study 7381310 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer tutoring sessions participation frequency.
Number of subjects: 60
Study 7381310 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 60
Study 28799963 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1427
Study 27480987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste alone
Number of subjects: 45
Study 27480987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish plus fluoride toothpaste
Number of subjects: 45
Study 27480987 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP plus crème plus fluoride toothpaste
Number of subjects: 45
Study 27480987 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish and CPP-ACP crème plus fluoride toothpaste
Number of subjects: 45
Study 25550295 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer sex video intervention
Number of subjects: 1252
Study 25550295 — intervention group
Group type: COMPARATOR
Intervention: Standard waiting room experience
Number of subjects: 1252
Study 22751169 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 8
Study 20035984 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U BTX‐A initially, with subsequent injections between 100 and 300 U
Number of subjects: 34
Study 20035984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose alteration in BTX‐A
Number of subjects: 34
Study 20035984 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated injections of BTX‐A
Number of subjects: 34
Study 18703937 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 2185
Study 18703937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 15758796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (2 mg daily)
Number of subjects: 711
Study 15758796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 12618254 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric vacuum aspiration
Number of subjects: 84
Study 12618254 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration
Number of subjects: 84
Study 12618254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 84
Study 10966890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion (10% triacylglycerol emulsion) + heparin (200 U bolus followed by 0.2 U*min(‐)(1)*kg body wt(‐)(1)) for 180 min
Number of subjects: 30
Study 10966890 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl for 180 min
Number of subjects: 30
Study 10966890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion + heparin with propranolol infusion (n = 8)
Number of subjects: 30
Study 8828369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin high-dose (300 x 10^4 units)
Number of subjects: 45
Study 8828369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin low-dose (100 x 10^4 units)
Number of subjects: 45
Study 8828369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 45
Study 8828369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin administration
Number of subjects: 45
Study 1325880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day for 3 weeks and then 20 mg/day for 4 weeks (n = 12)
Number of subjects: 15
Study 1325880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 15
Study 1325880 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin 1-8 mg/day
Number of subjects: 15